JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

Search

Vertex Pharmaceuticals Inc

Closed

SectorHealthcare

471.19 1.95

Overview

Share price change

24h

Current

Min

461.08

Max

473

Key metrics

By Trading Economics

Income

-267M

646M

Sales

-142M

2.8B

P/E

Sector Avg

30.42

40.048

EPS

4.06

Profit margin

23.33

Employees

6,100

EBITDA

-404M

782M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+10.7% upside

Dividends

By Dow Jones

Next Earnings

3 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-1.4B

118B

Previous open

469.24

Previous close

471.19

News Sentiment

By Acuity

9%

91%

10 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

4 Aug 2025, 21:21 UTC

Earnings
Major Market Movers

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 Aug 2025, 20:45 UTC

Earnings

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

5 May 2025, 21:00 UTC

Earnings

Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge

10 Feb 2025, 22:11 UTC

Earnings

Vertex Pharmaceuticals Posts Higher 4Q Revenue

4 Aug 2025, 20:15 UTC

Earnings

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 Aug 2025, 20:13 UTC

Earnings

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

6 May 2025, 16:31 UTC

Earnings

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com

5 May 2025, 20:03 UTC

Earnings

Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX

5 May 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 1Q Net $646.3M >VRTX

5 May 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX

5 May 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX

5 May 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 1Q Adj EPS $4.06 >VRTX

27 Apr 2025, 11:00 UTC

Top News

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

11 Apr 2025, 09:30 UTC

Top News

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

28 Feb 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 Feb 2025, 21:12 UTC

Earnings

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

11 Feb 2025, 14:21 UTC

Earnings

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

10 Feb 2025, 21:12 UTC

Earnings

Vertex Pharmaceuticals: Duncan McKechnie, Current Head of N Amer Comml, to Assume Role of Chief Comml Officer

10 Feb 2025, 21:12 UTC

Earnings

Vertex Pharmaceuticals CFO Charlie Wagner to Assume Additional Role of COO

10 Feb 2025, 21:11 UTC

Earnings

Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1

10 Feb 2025, 21:04 UTC

Earnings

Vertex Pharmaceuticals Sees Combined Non-GAAP R&D, AIPR&D and SG&A Expenses $4.9B to $5.0 B >VRTX

10 Feb 2025, 21:04 UTC

Earnings

Vertex Pharmaceuticals Sees Combined GAAP R&D, AIPR&D and SG&A Expenses $5.55B to $5.7 B >VRTX

10 Feb 2025, 21:02 UTC

Earnings

Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX

Peer Comparison

Price change

Vertex Pharmaceuticals Inc Forecast

Price Target

By TipRanks

10.7% upside

12 Months Forecast

Average 511.59 USD  10.7%

High 621 USD

Low 424 USD

Based on 25 Wall Street analysts offering 12 month price targets forVertex Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

25 ratings

12

Buy

13

Hold

0

Sell

Technical Score

By Trading Central

428.545 / 498.65Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

10 / 374 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.